Risk Factors for Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy Clinical Trial

Official title:

Genetic and Environmental Risk Factors for PSP

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00431301
• Other study ID #: 1R01AG024040-01A2
• Secondary ID: 1R01AG024040-01A
• Status: Completed
• Phase: N/A
• First received: February 1, 2007
• Last updated: April 6, 2017
• Start date: August 2006
• Est. completion date: June 2013

Study information

• Verified date: April 2017
• Source: University of Louisville
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Progressive supranuclear palsy (PSP) is the most common atypical parkinsonian movement disorder. This study will determine the role of specific genetic, occupational and environmental components in the development of PSP by evaluating patients with this disorder and age and gender matched controls.

Description:

This proposal will determine: (1) if there is an association between PSP and specific genes of interest; (2) if there is an association between PSP and occupational and/or environmental chemical exposures functionally or structurally similar to known parkinsonian toxicants; and (3) if hypertension or traumatic brain injury prior to symptom-onset is associated with PSP. To disentangle the complex etiology of PSP, this case-control multicenter study involves 500 PSP cases, 500 age/gender matched primary controls, and 500 secondary controls for genetic confirmation. Understanding the etiology of PSP may also help explain the causes of other related diseases such as Alzheimer's disease. This multidisciplinary team of movement disorder specialists, epidemiologists, geneticists, biostatisticians, industrial hygienist and toxicologist is well suited to unravel the etiology of PSP.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 942
• Est. completion date: June 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• PSP patients able to visit one of the screening sites for diagnostic confirmation and able to participate in a one hour telephone interview

Exclusion Criteria:

• No other major neurological disorders

• Unable to communicate by telephone

Related Conditions & MeSH terms

• Progressive Supranuclear Palsy
• Supranuclear Palsy, Progressive

Locations

Country	Name	City	State
Canada	University of Toronto	Toronto	Ontario
United States	Emory College of Medicine	Atlanta	Georgia
United States	University of Colorado	Aurora	Colorado
United States	University of Maryland	Baltimore	Maryland
United States	University of Alabama, Birmingham	Birmingham	Alabama
United States	Rush University	Chicago	Illinois
United States	Case Western University	Cleveland	Ohio
United States	University of Kansas	Kansas City	Kansas
United States	UCLA	Los Angeles	California
United States	University of Louisville	Louisville	Kentucky

Sponsors (2)

Lead Sponsor	Collaborator
University of Louisville	National Institute on Aging (NIA)

Countries where clinical trial is conducted

United States,  Canada, 

External Links

•   PSP study information website